Clinical Trial Update: Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nogapendekin alfa-inbakicept in combination with iNKT cell therapy for critically ill adults with severe community-acquired pneumonia, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Community-acquired Pneumonia
• Respiratory Distress Syndrome
• Sepsis

Drugs mentioned

• Nogapendekin-alfa Inbakicept
• iNKT cell therapy (invariant natural killer T cell adoptive transfer)

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum | Phase 2 | Status: NOT_YET_RECRUITING